Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068552 | 1.00 | MTNR1A (0.57) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL16645248 | 0.91 | MTNR1A (0.48) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL19068566 | 0.91 | MTNR1A (0.48) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL1196780 | 0.90 | HTR2B (0.61) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL1196782 | 0.90 | HTR2B (0.61) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL7759517 | 0.88 | HTR2B (0.61) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL7759512 | 0.88 | HTR2B (0.61) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL6302625 | 0.83 | HTR2B (0.68) | MTNR1AMTNR1BCYP3A4KDM4ECYP1A2 | |
| SCHEMBL17938401 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BHPGDHTR2BHTR1A | |
| SCHEMBL16645246 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BHPGDHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695174-B2 | Inhibitor of breast cancer resistance protein (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695174-B2 | Inhibitor of breast cancer resistance protein (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-28 | — | — | US | disclosed |
| WO-2015054132-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214984-A1 | INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP) | BRCA1, ABCC1, IMPA1 | MTNR1A 364/4885MTNR1B 270/4885CYP3A4 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.